Literature DB >> 17347655

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics.

Leslie M Shaw1, Magdalena Korecka, Christopher M Clark, Virginia M-Y Lee, John Q Trojanowski.   

Abstract

Rapid progress towards understanding the molecular underpinnings of neurodegenerative disorders such as Alzheimer's disease is revolutionizing drug discovery for these conditions. Furthermore, the development of models for these disorders is accelerating efforts to translate insights related to neurodegenerative mechanisms into disease-modifying therapies. However, there is an urgent need for biomarkers to diagnose neurodegenerative disorders early in their course, when therapy is likely to be most effective, and to monitor responses of patients to new therapies. As research related to this need is currently most advanced for Alzheimer's disease, this Review focuses on progress in the development and validation of biomarkers to improve the diagnosis and treatment of Alzheimer's disease and related disorders.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17347655     DOI： 10.1038/nrd2176

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  128 in total

Review 1.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort.

Authors:  A Caroli; G B Frisoni
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

4.  Spontaneous brain activity observed with functional magnetic resonance imaging as a potential biomarker in neuropsychiatric disorders.

Authors:  Yuan Zhou; Kun Wang; Yong Liu; Ming Song; Sonya W Song; Tianzi Jiang
Journal:  Cogn Neurodyn       Date:  2010-08-03       Impact factor: 5.082

Review 5.  The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Enchi Liu; John C Morris; Ronald C Petersen; Andrew J Saykin; Mark E Schmidt; Leslie Shaw; Judith A Siuciak; Holly Soares; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2011-11-02       Impact factor: 21.566

6.  Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.

Authors:  Mahesh N Samtani; Nandini Raghavan; Yingqi Shi; Gerald Novak; Michael Farnum; Victor Lobanov; Tim Schultz; Eric Yang; Allitia DiBernardo; Vaibhav A Narayan
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  Paxillin and hydrogen peroxide-inducible clone 5 expression and distribution in control and Alzheimer disease hippocampi.

Authors:  John Caltagarone; Ronald L Hamilton; Geoffrey Murdoch; Zheng Jing; Donald B DeFranco; Robert Bowser
Journal:  J Neuropathol Exp Neurol       Date:  2010-04       Impact factor: 3.685

8.  Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment.

Authors:  William T Hu; Alice Chen-Plotkin; Steven E Arnold; Murray Grossman; Christopher M Clark; Leslie M Shaw; Eve Pickering; Max Kuhn; Yu Chen; Leo McCluskey; Lauren Elman; Jason Karlawish; Howard I Hurtig; Andrew Siderowf; Virginia M-Y Lee; Holly Soares; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2010-03-16       Impact factor: 17.088

9.  Tau is reduced in AD plasma and validation of employed ELISA methods.

Authors:  D Larry Sparks; Richard J Kryscio; Marwan N Sabbagh; Chuck Ziolkowski; Yushun Lin; Lisa M Sparks; Carolyn Liebsack; Sherry Johnson-Traver
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

10.  Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls.

Authors:  Yi-Yu Chou; Natasha Leporé; Christina Avedissian; Sarah K Madsen; Neelroop Parikshak; Xue Hua; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Arthur W Toga; Paul M Thompson
Journal:  Neuroimage       Date:  2009-02-21       Impact factor: 6.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.